Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa
TYG100 utilizes proprietary S-TIR™ technology platform enabling specific B cell and T cell responses against tumor antigensFOSTER CITY, Calif. and...